{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:26:31Z","timestamp":1787163991128,"version":"build-2736575974"},"publisher-location":"New York, NY","reference-count":188,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_3","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:01:35Z","timestamp":1753707695000},"page":"53-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases"],"prefix":"10.1007","author":[{"given":"Merryl","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Echigoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"4","key":"3_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41576-022-00556-8","volume":"24","author":"ME Rogalska","year":"2023","unstructured":"Rogalska ME, Vivori C, Valc\u00e1rcel J (2023) Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects. Nat Rev Genet 24(4):251\u2013269. https:\/\/doi.org\/10.1038\/s41576-022-00556-8","journal-title":"Nat Rev Genet"},{"key":"3_CR2","doi-asserted-by":"publisher","unstructured":"Wilton-Clark H, Yokota T (2023) Recent trends in antisense therapies for Duchenne muscular dystrophy. Pharmaceutics 15(3). https:\/\/doi.org\/10.3390\/pharmaceutics15030778","DOI":"10.3390\/pharmaceutics15030778"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJA, Davies KE (2023) Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov 22:917. https:\/\/doi.org\/10.1038\/s41573-023-00775-6","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A (2024) Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med (Lond) 4(1):6. https:\/\/doi.org\/10.1038\/s43856-023-00419-1","journal-title":"Commun Med (Lond)"},{"issue":"6524","key":"3_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1126\/science.aba4515","volume":"371","author":"A Ferlini","year":"2021","unstructured":"Ferlini A, Goyenvalle A, Muntoni F (2021) RNA-targeted drugs for neuromuscular diseases. Science 371(6524):29\u201331. https:\/\/doi.org\/10.1126\/science.aba4515","journal-title":"Science"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M (2023) Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 51:2529. https:\/\/doi.org\/10.1093\/nar\/gkad067","journal-title":"Nucleic Acids Res"},{"key":"3_CR7","first-page":"38","volume":"92","author":"M Bege","year":"2022","unstructured":"Bege M, Borb\u00e1s A (2022) Rise and fall of Fomivirsen, the first approved gene silencing medicine \u2013 a historical review. Acta Pharm Hung 92:38\u201344","journal-title":"Acta Pharm Hung"},{"key":"3_CR8","doi-asserted-by":"publisher","unstructured":"Haque US, Yokota T (2023) Enhancing antisense oligonucleotide-based therapeutic delivery with DG9, a versatile cell-penetrating peptide. Cells 12(19). https:\/\/doi.org\/10.3390\/cells12192395","DOI":"10.3390\/cells12192395"},{"key":"3_CR9","doi-asserted-by":"publisher","unstructured":"Leckie J, Yokota T (2024) Potential of cell-penetrating peptide-conjugated antisense oligonucleotides for the treatment of SMA. Molecules 29(11). https:\/\/doi.org\/10.3390\/molecules29112658","DOI":"10.3390\/molecules29112658"},{"issue":"8","key":"3_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41583-023-00717-6","volume":"24","author":"D Nikom","year":"2023","unstructured":"Nikom D, Zheng S (2023) Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nat Rev Neurosci 24(8):457\u2013473. https:\/\/doi.org\/10.1038\/s41583-023-00717-6","journal-title":"Nat Rev Neurosci"},{"issue":"9\u201310","key":"3_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1089\/hum.2023.059","volume":"34","author":"S Fatehi","year":"2023","unstructured":"Fatehi S, Marks RM, Rok MJ, Perillat L, Ivakine EA, Cohn RD (2023) Advances in CRISPR\/Cas9 genome editing for the treatment of muscular dystrophies. Hum Gene Ther 34(9\u201310):388\u2013403. https:\/\/doi.org\/10.1089\/hum.2023.059","journal-title":"Hum Gene Ther"},{"issue":"8","key":"3_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/hmg\/ddac286","volume":"32","author":"S Enkhjargal","year":"2023","unstructured":"Enkhjargal S, Sugahara K, Khaledian B, Nagasaka M, Inagaki H, Kurahashi H, Koshimizu H, Toda T, Taniguchi-Ikeda M (2023) Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant. Hum Mol Genet 32(8):1301\u20131312. https:\/\/doi.org\/10.1093\/hmg\/ddac286","journal-title":"Hum Mol Genet"},{"key":"3_CR13","doi-asserted-by":"publisher","unstructured":"Anwar S, Yokota T (2024) The Dysferlinopathies conundrum: clinical spectra, disease mechanism and genetic approaches for treatments. Biomol Ther 14(3). https:\/\/doi.org\/10.3390\/biom14030256","DOI":"10.3390\/biom14030256"},{"issue":"1","key":"3_CR14","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41467-023-37619-1","volume":"14","author":"N Hu","year":"2023","unstructured":"Hu N, Kim E, Antoury L, Wheeler TM (2023) Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy. Nat Commun 14(1):1956. https:\/\/doi.org\/10.1038\/s41467-023-37619-1","journal-title":"Nat Commun"},{"issue":"8","key":"3_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nm.4367","volume":"23","author":"DU Kemaladewi","year":"2017","unstructured":"Kemaladewi DU, Maino E, Hyatt E, Hou H, Ding M, Place KM, Zhu X, Bassi P, Baghestani Z, Deshwar AG, Merico D, Xiong HY, Frey BJ, Wilson MD, Ivakine EA, Cohn RD (2017) Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med 23(8):984\u2013989. https:\/\/doi.org\/10.1038\/nm.4367","journal-title":"Nat Med"},{"key":"3_CR16","doi-asserted-by":"publisher","unstructured":"\u010cadoni\u010d K, Sajovic J, Hawlina M, Fakin A (2023) Natural disease course in usher syndrome patients harboring USH2A variant p.Cys870* in exon 13, amenable to exon skipping therapy. Genes (Basel) 14(3). https:\/\/doi.org\/10.3390\/genes14030652","DOI":"10.3390\/genes14030652"},{"key":"3_CR17","doi-asserted-by":"publisher","unstructured":"Major L, McClements ME, MacLaren RE (2023) A review of CRISPR tools for treating usher syndrome: applicability, safety, efficiency, and in vivo delivery. Int J Mol Sci 24(8). https:\/\/doi.org\/10.3390\/ijms24087603","DOI":"10.3390\/ijms24087603"},{"key":"3_CR18","doi-asserted-by":"publisher","unstructured":"Bischof J, Hierl M, Koller U (2024) Emerging gene therapeutics for epidermolysis bullosa under development. Int J Mol Sci 25(4). https:\/\/doi.org\/10.3390\/ijms25042243","DOI":"10.3390\/ijms25042243"},{"key":"3_CR19","doi-asserted-by":"publisher","unstructured":"Anwar S, Yokota T (2023) Navigating the complex landscape of Fibrodysplasia Ossificans Progressiva: from current paradigms to therapeutic Frontiers. Genes (Basel) 14(12). https:\/\/doi.org\/10.3390\/genes14122162","DOI":"10.3390\/genes14122162"},{"issue":"9","key":"3_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","volume":"5","author":"KJ Nowak","year":"2004","unstructured":"Nowak KJ, Davies KE (2004) Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5(9):872\u2013876. https:\/\/doi.org\/10.1038\/sj.embor.7400221","journal-title":"EMBO Rep"},{"key":"3_CR21","first-page":"457","volume":"24","author":"EP Hoffman","year":"1992","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1992) Dystrophin: the protein product of the Duchene muscular dystrophy locus. 1987. Biotechnology 24:457\u2013466","journal-title":"Biotechnology"},{"issue":"3","key":"3_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/brainsci5030275","volume":"5","author":"B Nichols","year":"2015","unstructured":"Nichols B, Takeda S, Yokota T (2015) Nonmechanical roles of dystrophin and associated proteins in exercise, neuromuscular junctions, and brains. Brain Sci 5(3):275\u2013298. https:\/\/doi.org\/10.3390\/brainsci5030275","journal-title":"Brain Sci"},{"issue":"11","key":"3_CR23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11):1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Mol Ther"},{"issue":"3","key":"3_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR, Gumienny F, Huang N, Wilton SD, Flanigan KM (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4(3):199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscul Dis"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O, Aoki Y, Takeda S, Yokota T (2017) Systemic delivery of Morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_17","journal-title":"Methods Mol Biol"},{"issue":"9","key":"3_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y, Kolski H (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141\u20131152. https:\/\/doi.org\/10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102(1):198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2(1):90\u201395","journal-title":"Genomics"},{"issue":"2","key":"3_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135\u2013144. https:\/\/doi.org\/10.1002\/mus.20586","journal-title":"Muscle Nerve"},{"issue":"4","key":"3_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36(4):395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758","journal-title":"Hum Mutat"},{"issue":"3","key":"3_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"issue":"4","key":"3_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jpm8040041","volume":"8","author":"Y Echigoya","year":"2018","unstructured":"Echigoya Y, Lim KRQ, Nakamura A, Yokota T (2018) Multiple exon skipping in the Duchenne muscular dystrophy hot spots: prospects and challenges. J Pers Med 8(4):41","journal-title":"J Pers Med"},{"key":"3_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.crtox.2024.100182","volume":"7","author":"U Sabrina Haque","year":"2024","unstructured":"Sabrina Haque U, Kohut M, Yokota T (2024) Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne muscular dystrophy: from FDA-approved drugs to peptide-conjugated ASO. Curr Res Toxicol 7:100182. https:\/\/doi.org\/10.1016\/j.crtox.2024.100182","journal-title":"Curr Res Toxicol"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3233\/jnd-230107","volume":"11","author":"S Nicolau","year":"2024","unstructured":"Nicolau S, Malhotra J, Kaler M, Magistrado-Coxen P, Iammarino MA, Reash NF, Frair EC, Wijeratne S, Kelly BJ, White P, Lowes LP, Waldrop MA, Flanigan KM (2024) Increase in full-length dystrophin by exon skipping in Duchenne muscular dystrophy patients with single exon duplications: an open-label study. J Neuromuscul Dis 11:679. https:\/\/doi.org\/10.3233\/jnd-230107","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"3_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N, Motoki H, Miyazaki D, Nishizawa H, Echigoya Y, Yokota T, Aoki Y, Takeda S (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663\u2013667. https:\/\/doi.org\/10.1038\/jhg.2016.28","journal-title":"J Hum Genet"},{"issue":"5","key":"3_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/ana.26461","volume":"92","author":"J Poyatos-Garc\u00eda","year":"2022","unstructured":"Poyatos-Garc\u00eda J, Mart\u00ed P, Liquori A et al (2022) Dystrophinopathy phenotypes and modifying factors in DMD exon 45-55 deletion. Ann Neurol 92(5):793\u2013806. https:\/\/doi.org\/10.1002\/ana.26461","journal-title":"Ann Neurol"},{"issue":"12","key":"3_CR37","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1002\/acn3.51925","volume":"10","author":"A Nakamura","year":"2023","unstructured":"Nakamura A, Matsumura T, Ogata K et al (2023) Natural history of Becker muscular dystrophy: a multicenter study of 225 patients. Ann Clin Transl Neurol 10(12):2360\u20132372. https:\/\/doi.org\/10.1002\/acn3.51925","journal-title":"Ann Clin Transl Neurol"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","volume":"27","author":"Y Echigoya","year":"2019","unstructured":"Echigoya Y, Lim KRQ, Melo D, Bao B, Trieu N, Mizobe Y, Maruyama R, Mamchaoui K, Tanihata J, Aoki Y, Takeda S, Mouly V, Duddy W, Yokota T (2019) Exons 45-55 skipping using mutation-tailored cocktails of antisense Morpholinos in the DMD gene. Mol Ther 27:2005. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.012","journal-title":"Mol Ther"},{"key":"3_CR39","doi-asserted-by":"publisher","unstructured":"Lim KRQ, Woo S, Melo D, Huang Y, Dzierlega K, Shah MNA, Aslesh T, Roshmi RR, Echigoya Y, Maruyama R, Moulton HM, Yokota T (2022) Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 119(9). https:\/\/doi.org\/10.1073\/pnas.2112546119","DOI":"10.1073\/pnas.2112546119"},{"key":"3_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"3_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D, Nishizawa H, Inaba Y, Fueki N, Maruyama R, Echigoya Y, Yokota T (2017) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"2","key":"3_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"C Beroud","year":"2007","unstructured":"Beroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossee M, Pages M, Rivier F, Danos O, Garcia L, Claustres M (2007) Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 28(2):196\u2013202. https:\/\/doi.org\/10.1002\/humu.20428","journal-title":"Hum Mutat"},{"issue":"16","key":"3_CR43","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KR, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","volume":"27","author":"KRQ Lim","year":"2019","unstructured":"Lim KRQ, Echigoya Y, Nagata T, Kuraoka M, Kobayashi M, Aoki Y, Partridge T, Maruyama R, Takeda S, Yokota T (2019) Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates. Mol Ther 27(1):76\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.011","journal-title":"Mol Ther"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/dddt.s97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/dddt.s97635","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"3_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/jnd-210643","volume":"8","author":"CM McDonald","year":"2021","unstructured":"McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, Goemans N, Mercuri E, Khan N, Koenig E, Malhotra J, Zhang W, Han B, Mendell JR (2021) Open-label evaluation of Eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J Neuromuscul Dis 8(6):989\u20131001. https:\/\/doi.org\/10.3233\/jnd-210643","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"3_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/jnd-200548","volume":"8","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Khan N, Sha N, Eliopoulos H, McDonald CM, Goemans N, Mercuri E, Lowes LP, Alfano LN (2021) Comparison of Long-term ambulatory function in patients with Duchenne muscular dystrophy treated with Eteplirsen and matched natural history controls. J Neuromuscul Dis 8(4):469\u2013479. https:\/\/doi.org\/10.3233\/jnd-200548","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"3_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/jnd-210665","volume":"9","author":"O Mitelman","year":"2022","unstructured":"Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N, McDonald CM, Mercuri E, Mendell JR (2022) A combined prospective and retrospective comparison of Long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with Long-term Eteplirsen treatment. J Neuromuscul Dis 9(1):39\u201352. https:\/\/doi.org\/10.3233\/jnd-210665","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"3_CR49","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mus.28075","volume":"70","author":"J Iff","year":"2024","unstructured":"Iff J, Done N, Tuttle E, Zhong Y, Wei F, Darras BT, McDonald CM, Mercuri E, Muntoni F (2024) Survival among patients receiving eteplirsen for up to 8\u2009years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle Nerve 70(1):60\u201370. https:\/\/doi.org\/10.1002\/mus.28075","journal-title":"Muscle Nerve"},{"issue":"11","key":"3_CR50","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25(11):2561\u20132572. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"issue":"W1","key":"3_CR51","doi-asserted-by":"publisher","first-page":"W193","DOI":"10.1093\/nar\/gkab442","volume":"49","author":"S Chiba","year":"2021","unstructured":"Chiba S, Lim KRQ, Sheri N, Anwar S, Erkut E, Shah MNA, Aslesh T, Woo S, Sheikh O, Maruyama R, Takano H, Kunitake K, Duddy W, Okuno Y, Aoki Y, Yokota T (2021) eSkip-finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping. Nucleic Acids Res 49(W1):W193\u2013w198. https:\/\/doi.org\/10.1093\/nar\/gkab442","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"3_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2023.2169070","volume":"23","author":"G Filonova","year":"2023","unstructured":"Filonova G, Aartsma-Rus A (2023) Next steps for the optimization of exon therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 23(2):133\u2013143. https:\/\/doi.org\/10.1080\/14712598.2023.2169070","journal-title":"Expert Opin Biol Ther"},{"issue":"13","key":"3_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33417","volume":"10","author":"Z Dai","year":"2024","unstructured":"Dai Z, Wang G, Zhang J, Zhao Q, Jiang L (2024) Adverse events associated with eteplirsen: a disproportionality analysis using the 2016-2023 FAERS data. Heliyon 10(13):e33417. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33417","journal-title":"Heliyon"},{"key":"3_CR54","unstructured":"Rao VK, Finanger EL, Previtera ML, Crozier RA, Magnus L, Hoffman EP, Komaki H, Aoki Y, Clemens PR (2024) A Phase 1\/2 study of NS-050\/NCNP-03, an investigational exon 50 skipping therapy, in boys with Duchenne muscular dystrophy (Meteor50): Trial design. The 2024 MDA Annual Meeting March 3\u20136:M160"},{"issue":"2","key":"3_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/npr2.12335","volume":"43","author":"T Ishizuka","year":"2023","unstructured":"Ishizuka T, Komaki H, Asahina Y, Nakamura H, Motohashi N, Takeshita E, Shimizu-Motohashi Y, Ishiyama A, Yonee C, Maruyama S, Hida E, Aoki Y (2023) Systemic administration of the antisense oligonucleotide NS-089\/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: study protocol for a phase I\/II clinical trial. Neuropsychopharmacol Rep 43(2):277\u2013286. https:\/\/doi.org\/10.1002\/npr2.12335","journal-title":"Neuropsychopharmacol Rep"},{"key":"3_CR56","doi-asserted-by":"publisher","unstructured":"Erkut E, Yokota T (2022) CRISPR therapeutics for Duchenne muscular dystrophy. Int J Mol Sci 23(3). https:\/\/doi.org\/10.3390\/ijms23031832","DOI":"10.3390\/ijms23031832"},{"key":"3_CR57","doi-asserted-by":"publisher","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S (2024) CRISPR-based gene therapies: from preclinical to clinical treatments. Cells 13(10). https:\/\/doi.org\/10.3390\/cells13100800","DOI":"10.3390\/cells13100800"},{"issue":"2","key":"3_CR58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","volume":"60","author":"FJ Mojica","year":"2005","unstructured":"Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60(2):174\u2013182. https:\/\/doi.org\/10.1007\/s00239-004-0046-3","journal-title":"J Mol Evol"},{"issue":"6","key":"3_CR59","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","volume":"43","author":"R Jansen","year":"2002","unstructured":"Jansen R, Embden JD, Gaastra W, Schouls LM (2002) Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43(6):1565\u20131575","journal-title":"Mol Microbiol"},{"issue":"5819","key":"3_CR60","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709\u20131712. https:\/\/doi.org\/10.1126\/science.1138140","journal-title":"Science"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.1254445","volume":"345","author":"C Long","year":"2014","unstructured":"Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN (2014) Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA. Science 345:1184. https:\/\/doi.org\/10.1126\/science.1254445","journal-title":"Science"},{"issue":"6271","key":"3_CR62","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA, Cong L, Zhang F, Vandenberghe LH, Church GM, Wagers AJ (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351(6271):407\u2013411. https:\/\/doi.org\/10.1126\/science.aad5177","journal-title":"Science"},{"issue":"6271","key":"3_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351(6271):403\u2013407. https:\/\/doi.org\/10.1126\/science.aad5143","journal-title":"Science"},{"issue":"6271","key":"3_CR64","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351(6271):400\u2013403. https:\/\/doi.org\/10.1126\/science.aad5725","journal-title":"Science"},{"key":"3_CR65","doi-asserted-by":"publisher","unstructured":"Lim KRQ, Yoon C, Yokota T (2018) Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy. J Pers Med 8(4). https:\/\/doi.org\/10.3390\/jpm8040038","DOI":"10.3390\/jpm8040038"},{"issue":"6410","key":"3_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, Harron R, Stathopoulou TR, Massey C, Shelton JM, Bassel-Duby R, Piercy RJ, Olson EN (2018) Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362(6410):86\u201391. https:\/\/doi.org\/10.1126\/science.aau1549","journal-title":"Science"},{"key":"3_CR67","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA (2015) Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6:6244. https:\/\/doi.org\/10.1038\/ncomms7244","journal-title":"Nat Commun"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, Karumbayaram S, Kumagai-Cresse C, Wang D, Zack JA, Kohn DB, Nakano A, Nelson SF, Miceli MC, Spencer MJ, Pyle AD (2016) A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18:533. https:\/\/doi.org\/10.1016\/j.stem.2016.01.021","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3_CR69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","volume":"4","author":"HL Li","year":"2015","unstructured":"Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, Hotta A (2015) Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 4(1):143\u2013154. https:\/\/doi.org\/10.1016\/j.stemcr.2014.10.013","journal-title":"Stem Cell Reports"},{"issue":"1","key":"3_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13395-024-00353-3","volume":"14","author":"J Poyatos-Garc\u00eda","year":"2024","unstructured":"Poyatos-Garc\u00eda J, Soblechero-Mart\u00edn P, Liquori A, L\u00f3pez-Mart\u00ednez A, Maestre P, Gonz\u00e1lez-Romero E, V\u00e1zquez-Manrique RP, Muelas N, Garc\u00eda-Garc\u00eda G, Ohana J, Arechavala-Gomeza V, V\u00edlchez JJ (2024) Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model. Skelet Muscle 14(1):21. https:\/\/doi.org\/10.1186\/s13395-024-00353-3","journal-title":"Skelet Muscle"},{"issue":"3","key":"3_CR71","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163(3):759\u2013771. https:\/\/doi.org\/10.1016\/j.cell.2015.09.038","journal-title":"Cell"},{"issue":"3","key":"3_CR72","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","volume":"60","author":"S Shmakov","year":"2015","unstructured":"Shmakov S, Abudayyeh OO, Makarova KS, Wolf YI, Gootenberg JS, Semenova E, Minakhin L, Joung J, Konermann S, Severinov K, Zhang F, Koonin EV (2015) Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell 60(3):385\u2013397. https:\/\/doi.org\/10.1016\/j.molcel.2015.10.008","journal-title":"Mol Cell"},{"issue":"4","key":"3_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1602814","volume":"3","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Long C, Li H, McAnally JR, Baskin KK, Shelton JM, Bassel-Duby R, Olson EN (2017) CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci Adv 3(4):e1602814. https:\/\/doi.org\/10.1126\/sciadv.1602814","journal-title":"Sci Adv"},{"issue":"19","key":"3_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38588","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Han H (2024) Strategies for improving the genome-editing efficiency of class 2 CRISPR\/Cas system. Heliyon 10(19):e38588. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38588","journal-title":"Heliyon"},{"key":"3_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/science.add8643","volume":"379","author":"JY Wang","year":"2023","unstructured":"Wang JY, Doudna JA (2023) CRISPR technology: a decade of genome editing is only the beginning. Science 379:eadd8643. https:\/\/doi.org\/10.1126\/science.add8643","journal-title":"Science"},{"issue":"5","key":"3_CR76","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","volume":"187","author":"M Pacesa","year":"2024","unstructured":"Pacesa M, Pelea O, Jinek M (2024) Past, present, and future of CRISPR genome editing technologies. Cell 187(5):1076\u20131100. https:\/\/doi.org\/10.1016\/j.cell.2024.01.042","journal-title":"Cell"},{"issue":"7","key":"3_CR77","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archneur.1976.00500070055011","volume":"33","author":"S Kamoshita","year":"1976","unstructured":"Kamoshita S, Konishi Y, Segawa M, Fukuyama Y (1976) Congenital muscular dystrophy as a disease of the central nervous system. Arch Neurol 33(7):513\u2013516","journal-title":"Arch Neurol"},{"issue":"3","key":"3_CR78","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ng1193-283","volume":"5","author":"T Toda","year":"1993","unstructured":"Toda T, Segawa M, Nomura Y, Nonaka I, Masuda K, Ishihara T, Sakai M, Tomita I, Origuchi Y, Suzuki M et al (1993) Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 5(3):283\u2013286. https:\/\/doi.org\/10.1038\/ng1193-283","journal-title":"Nat Genet"},{"issue":"4","key":"3_CR79","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ajmg.a.30978","volume":"138","author":"M Watanabe","year":"2005","unstructured":"Watanabe M, Kobayashi K, Jin F, Park KS, Yamada T, Tokunaga K, Toda T (2005) Founder SVA retrotransposal insertion in Fukuyama-type congenital muscular dystrophy and its origin in Japanese and northeast Asian populations. Am J Med Genet A 138(4):344\u2013348. https:\/\/doi.org\/10.1002\/ajmg.a.30978","journal-title":"Am J Med Genet A"},{"issue":"6691","key":"3_CR80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/28653","volume":"394","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y, Segawa M, Yoshioka M, Saito K, Osawa M, Hamano K, Sakakihara Y, Nonaka I, Nakagome Y, Kanazawa I, Nakamura Y, Tokunaga K, Toda T (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394(6691):388\u2013392. https:\/\/doi.org\/10.1038\/28653","journal-title":"Nature"},{"issue":"1","key":"3_CR81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1212\/WNL.57.1.115","volume":"57","author":"YK Hayashi","year":"2001","unstructured":"Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, Nonaka I, Arahata K (2001) Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57(1):115\u2013121","journal-title":"Neurology"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-4-431-55678-7_6","volume-title":"Translational research in muscular dystrophy","author":"JJA Lee","year":"2016","unstructured":"Lee JJA, Yokota T (2016) Translational research in nucleic acid therapies for muscular dystrophies. In: Takeda S, Miyagoe-Suzuki Y, Mori-Yoshimura M (eds) Translational research in muscular dystrophy. Springer, Tokyo, pp 87\u2013102. https:\/\/doi.org\/10.1007\/978-4-431-55678-7_6"},{"issue":"6","key":"3_CR83","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s004390000421","volume":"107","author":"R Colombo","year":"2000","unstructured":"Colombo R, Bignamini AA, Carobene A, Sasaki J, Tachikawa M, Kobayashi K, Toda T (2000) Age and origin of the FCMD 3\u2032-untranslated-region retrotransposal insertion mutation causing Fukuyama-type congenital muscular dystrophy in the Japanese population. Hum Genet 107(6):559\u2013567","journal-title":"Hum Genet"},{"issue":"3","key":"3_CR84","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"issue":"7367","key":"3_CR85","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature10456","volume":"478","author":"M Taniguchi-Ikeda","year":"2011","unstructured":"Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu CC, Mori K, Oda T, Kuga A, Kurahashi H, Akman HO, DiMauro S, Kaji R, Yokota T, Takeda S, Toda T (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478(7367):127\u2013131. https:\/\/doi.org\/10.1038\/nature10456","journal-title":"Nature"},{"issue":"11","key":"3_CR86","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/jhg.2017.71","volume":"62","author":"K Kobayashi","year":"2017","unstructured":"Kobayashi K, Kato R, Kondo-Iida E, Taniguchi-Ikeda M, Osawa M, Saito K, Toda T (2017) Deep-intronic variant of fukutin is the most prevalent point mutation of Fukuyama congenital muscular dystrophy in Japan. J Hum Genet 62(11):945\u2013948. https:\/\/doi.org\/10.1038\/jhg.2017.71","journal-title":"J Hum Genet"},{"issue":"1","key":"3_CR87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ncn3.12687","volume":"12","author":"M Nakamori","year":"2024","unstructured":"Nakamori M (2024) Expanded-repeat-RNA-mediated disease mechanisms in myotonic dystrophy. Neurol Clin Neurosci 12(1):16\u201323. https:\/\/doi.org\/10.1111\/ncn3.12687","journal-title":"Neurol Clin Neurosci"},{"issue":"4","key":"3_CR88","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","volume":"68","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell 68(4):799\u2013808","journal-title":"Cell"},{"issue":"5049","key":"3_CR89","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","volume":"255","author":"M Mahadevan","year":"1992","unstructured":"Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcel\u00f3 J, O\u2019Hoy K et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2032 untranslated region of the gene. Science 255(5049):1253\u20131255. https:\/\/doi.org\/10.1126\/science.1546325","journal-title":"Science"},{"issue":"5049","key":"3_CR90","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1126\/science.1546326","volume":"255","author":"YH Fu","year":"1992","unstructured":"Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P et al (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255(5049):1256\u20131258","journal-title":"Science"},{"issue":"5531","key":"3_CR91","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.1062125","volume":"293","author":"CL Liquori","year":"2001","unstructured":"Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293(5531):864\u2013867. https:\/\/doi.org\/10.1126\/science.1062125","journal-title":"Science"},{"issue":"11","key":"3_CR92","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.biochi.2011.06.028","volume":"93","author":"AF Klein","year":"2011","unstructured":"Klein AF, Gasnier E, Furling D (2011) Gain of RNA function in pathological cases: focus on myotonic dystrophy. Biochimie 93(11):2006\u20132012. https:\/\/doi.org\/10.1016\/j.biochi.2011.06.028","journal-title":"Biochimie"},{"key":"3_CR93","doi-asserted-by":"publisher","unstructured":"Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22(4). https:\/\/doi.org\/10.3390\/molecules22040563","DOI":"10.3390\/molecules22040563"},{"key":"3_CR94","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Mart\u00ednez A, Soblechero-Mart\u00edn P et al (2020) An overview of alternative splicing defects implicated in myotonic dystrophy type I. Genes (Basel) 11(9). https:\/\/doi.org\/10.3390\/genes11091109","DOI":"10.3390\/genes11091109"},{"issue":"1","key":"3_CR95","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","volume":"10","author":"BN Charlet","year":"2002","unstructured":"Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002) Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10(1):45\u201353","journal-title":"Mol Cell"},{"issue":"1","key":"3_CR96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ng704","volume":"29","author":"RS Savkur","year":"2001","unstructured":"Savkur RS, Philips AV, Cooper TA (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29(1):40\u201347. https:\/\/doi.org\/10.1038\/ng704","journal-title":"Nat Genet"},{"issue":"6","key":"3_CR97","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nm.2374","volume":"17","author":"C Fugier","year":"2011","unstructured":"Fugier C, Klein AF, Hammer C et al (2011) Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 17(6):720\u2013725. https:\/\/doi.org\/10.1038\/nm.2374","journal-title":"Nat Med"},{"key":"3_CR98","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1038\/ncomms8205","volume":"6","author":"F Rau","year":"2015","unstructured":"Rau F, Laine J, Ramanoudjame L, Ferry A, Arandel L, Delalande O, Jollet A, Dingli F, Lee KY, Peccate C, Lorain S, Kabashi E, Athanasopoulos T, Koo T, Loew D, Swanson MS, Le Rumeur E, Dickson G, Allamand V, Marie J, Furling D (2015) Abnormal splicing switch of DMD\u2019S penultimate exon compromises muscle fibre maintenance in myotonic dystrophy. Nat Commun 6:7205. https:\/\/doi.org\/10.1038\/ncomms8205","journal-title":"Nat Commun"},{"key":"3_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103489","volume":"28","author":"M Pascual-Gilabert","year":"2023","unstructured":"Pascual-Gilabert M, Artero R, L\u00f3pez-Castel A (2023) The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discov Today 28:103489. https:\/\/doi.org\/10.1016\/j.drudis.2023.103489","journal-title":"Drug Discov Today"},{"issue":"7409","key":"3_CR100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"TM Wheeler","year":"2012","unstructured":"Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111\u2013115. https:\/\/doi.org\/10.1038\/nature11362","journal-title":"Nature"},{"key":"3_CR101","unstructured":"Letter from Ionis Pharmaceuticals & Biogen to the MDF Community (2017). http:\/\/us8.campaign-archive2.com\/?u=8f5969cac3271759ce78c8354&id=1109538bcf&e=[UNIQID]. Accessed Sep 2017"},{"issue":"3","key":"3_CR102","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s1474-4422(23)00001-7","volume":"22","author":"CA Thornton","year":"2023","unstructured":"Thornton CA, Moxley RT 3rd, Eichinger K et al (2023) Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial. Lancet Neurol 22(3):218\u2013228. https:\/\/doi.org\/10.1016\/s1474-4422(23)00001-7","journal-title":"Lancet Neurol"},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/srep02242","volume":"3","author":"M Koebis","year":"2013","unstructured":"Koebis M, Kiyatake T, Yamaura H, Nagano K, Higashihara M, Sonoo M, Hayashi Y, Negishi Y, Endo-Takahashi Y, Yanagihara D, Matsuda R, Takahashi MP, Nishino I, Ishiura S (2013) Ultrasound-enhanced delivery of morpholino with bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice. Sci Rep 3:2242. https:\/\/doi.org\/10.1038\/srep02242","journal-title":"Sci Rep"},{"issue":"5","key":"3_CR104","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/hmg\/8.5.855","volume":"8","author":"LV Anderson","year":"1999","unstructured":"Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8(5):855\u2013861","journal-title":"Hum Mol Genet"},{"issue":"7","key":"3_CR105","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1600-0854.2007.00573.x","volume":"8","author":"L Glover","year":"2007","unstructured":"Glover L, Brown RH Jr (2007) Dysferlin in membrane trafficking and patch repair. Traffic 8(7):785\u2013794. https:\/\/doi.org\/10.1111\/j.1600-0854.2007.00573.x","journal-title":"Traffic"},{"key":"3_CR106","unstructured":"Aoki M (2004) Dysferlinopathy. GeneReviews\u00ae. University of Washington, Seattle, p 1993\u20132017"},{"issue":"1","key":"3_CR107","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/1682","volume":"20","author":"J Liu","year":"1998","unstructured":"Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20(1):31\u201336. https:\/\/doi.org\/10.1038\/1682","journal-title":"Nat Genet"},{"issue":"1","key":"3_CR108","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0","volume":"49","author":"I Illa","year":"2001","unstructured":"Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P, Baiget M, Matsuda C, Brown RH (2001) Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 49(1):130\u2013134","journal-title":"Ann Neurol"},{"issue":"5","key":"3_CR109","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.amjms.2016.05.024","volume":"353","author":"NJ Patel","year":"2017","unstructured":"Patel NJ, Van Dyke KW, Espinoza LR (2017) Limb-girdle muscular dystrophy 2B and Miyoshi presentations of Dysferlinopathy. Am J Med Sci 353(5):484\u2013491. https:\/\/doi.org\/10.1016\/j.amjms.2016.05.024","journal-title":"Am J Med Sci"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"e56999","DOI":"10.3791\/56999","volume":"131","author":"JJA Lee","year":"2018","unstructured":"Lee JJA, Maruyama R, Sakurai H, Yokota T (2018) Cell membrane repair assay using a two-photon laser microscope. J Vis Exp 131:e56999\u2013e56999. https:\/\/doi.org\/10.3791\/56999","journal-title":"J Vis Exp"},{"issue":"7","key":"3_CR111","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1212\/01.wnl.0000204358.89303.81","volume":"66","author":"M Sinnreich","year":"2006","unstructured":"Sinnreich M, Therrien C, Karpati G (2006) Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66(7):1114\u20131116. https:\/\/doi.org\/10.1212\/01.wnl.0000204358.89303.81","journal-title":"Neurology"},{"issue":"8","key":"3_CR112","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ejhg.2010.4","volume":"18","author":"A Aartsma-Rus","year":"2010","unstructured":"Aartsma-Rus A, Singh KH, Fokkema IF, Ginjaar IB, van Ommen GJ, den Dunnen JT, van der Maarel SM (2010) Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 18(8):889\u2013894. https:\/\/doi.org\/10.1038\/ejhg.2010.4","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"3_CR113","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3233\/JND-150109","volume":"2","author":"F Barthelemy","year":"2015","unstructured":"Barthelemy F, Blouin C, Wein N, Mouly V, Courrier S, Dionnet E, Kergourlay V, Mathieu Y, Garcia L, Butler-Browne G, Lamaze C, Levy N, Krahn M, Bartoli M (2015) Exon 32 skipping of Dysferlin rescues membrane repair in patients\u2019 cells. J Neuromuscul Dis 2(3):281\u2013290. https:\/\/doi.org\/10.3233\/JND-150109","journal-title":"J Neuromuscul Dis"},{"key":"3_CR114","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","volume":"13","author":"JJA Lee","year":"2018","unstructured":"Lee JJA, Maruyama R, Duddy W, Sakurai H, Yokota T (2018) Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of Dysferlinopathy. Mol Ther Nucleic Acids 13:596\u2013604. https:\/\/doi.org\/10.1016\/j.omtn.2018.10.004","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"3_CR115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/nat.2019.0788","volume":"30","author":"N Verwey","year":"2020","unstructured":"Verwey N, Gazzoli I, Krause S, Mamchaoui K, Mouly V, Aartsma-Rus A (2020) Antisense-mediated skipping of Dysferlin exons in control and Dysferlinopathy patient-derived cells. Nucleic Acid Ther 30(2):71\u201379. https:\/\/doi.org\/10.1089\/nat.2019.0788","journal-title":"Nucleic Acid Ther"},{"key":"3_CR116","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/tacg.S187481","volume":"12","author":"Q Nguyen","year":"2019","unstructured":"Nguyen Q, Lim KRQ, Yokota T (2019) Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-\u03b12 chain-deficient congenital muscular dystrophy. Appl Clin Genet 12:113\u2013130. https:\/\/doi.org\/10.2147\/tacg.S187481","journal-title":"Appl Clin Genet"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/bs.ctm.2015.05.002","volume":"76","author":"M Durbeej","year":"2015","unstructured":"Durbeej M (2015) Laminin-alpha2 chain-deficient congenital muscular dystrophy: pathophysiology and development of treatment. Curr Top Membr 76:31\u201360. https:\/\/doi.org\/10.1016\/bs.ctm.2015.05.002","journal-title":"Curr Top Membr"},{"issue":"2","key":"3_CR118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11910-010-0092-8","volume":"10","author":"J Collins","year":"2010","unstructured":"Collins J, Bonnemann CG (2010) Congenital muscular dystrophies: toward molecular therapeutic interventions. Curr Neurol Neurosci Rep 10(2):83\u201391. https:\/\/doi.org\/10.1007\/s11910-010-0092-8","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"44","key":"3_CR119","doi-asserted-by":"publisher","first-page":"27664","DOI":"10.1074\/jbc.271.44.27664","volume":"271","author":"X Zhang","year":"1996","unstructured":"Zhang X, Vuolteenaho R, Tryggvason K (1996) Structure of the human laminin alpha2-chain gene (LAMA2), which is affected in congenital muscular dystrophy. J Biol Chem 271(44):27664\u201327669","journal-title":"J Biol Chem"},{"issue":"3","key":"3_CR120","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/gte.2006.0517","volume":"11","author":"O Siala","year":"2007","unstructured":"Siala O, Louhichi N, Triki C, Moriniere M, Rebai A, Richard P, Guicheney P, Baklouti F, Fakhfakh F (2007) Severe MDC1A congenital muscular dystrophy due to a splicing mutation in the LAMA2 gene resulting in exon skipping and significant decrease of mRNA level. Genet Test 11(3):199\u2013207. https:\/\/doi.org\/10.1089\/gte.2006.0517","journal-title":"Genet Test"},{"issue":"24","key":"3_CR121","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22(24):4914\u20134928. https:\/\/doi.org\/10.1093\/hmg\/ddt341","journal-title":"Hum Mol Genet"},{"key":"3_CR122","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fnmol.2020.00059","volume":"13","author":"KI Gawlik","year":"2020","unstructured":"Gawlik KI, Durbeej M (2020) A family of Laminin \u03b12 chain-deficient mouse mutants: advancing the research on LAMA2-CMD. Front Mol Neurosci 13:59. https:\/\/doi.org\/10.3389\/fnmol.2020.00059","journal-title":"Front Mol Neurosci"},{"key":"3_CR123","doi-asserted-by":"publisher","first-page":"251584142095219","DOI":"10.1177\/2515841420952194","volume":"12","author":"M Toms","year":"2020","unstructured":"Toms M, Pagarkar W, Moosajee M (2020) Usher syndrome: clinical features, molecular genetics and advancing therapeutics. Ther Adv Ophthalmol 12:2515841420952194. https:\/\/doi.org\/10.1177\/2515841420952194","journal-title":"Ther Adv Ophthalmol"},{"issue":"10","key":"3_CR124","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1167\/iovs.64.10.23","volume":"64","author":"KAJ Stephenson","year":"2023","unstructured":"Stephenson KAJ, Whelan L, Zhu J, Dockery A, Wynne NC, Cairns RM, Kirk C, Turner J, Duignan ES, O\u2019Byrne JJ, Silvestri G, Kenna PF, Farrar GJ, Keegan DJ (2023) Usher syndrome on the Island of Ireland: a genotype-phenotype review. Invest Ophthalmol Vis Sci 64(10):23. https:\/\/doi.org\/10.1167\/iovs.64.10.23","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15257770.2024.2344194","volume":"44","author":"F Ullah","year":"2024","unstructured":"Ullah F, Zeeshan Ali M, Ahmad S, Muzammal M, Khan S, Khan J, Ahmad Khan M (2024) Current updates on genetic spectrum of usher syndrome. Nucleosides Nucleotides Nucleic Acids 44:1\u201324. https:\/\/doi.org\/10.1080\/15257770.2024.2344194","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"3_CR126","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/jhg.2010.29","volume":"55","author":"D Yan","year":"2010","unstructured":"Yan D, Liu XZ (2010) Genetics and pathological mechanisms of usher syndrome. J Hum Genet 55(6):327\u2013335. https:\/\/doi.org\/10.1038\/jhg.2010.29","journal-title":"J Hum Genet"},{"issue":"1","key":"3_CR127","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/humu.21634","volume":"33","author":"C Vache","year":"2012","unstructured":"Vache C, Besnard T, le Berre P, Garcia-Garcia G, Baux D, Larrieu L, Abadie C, Blanchet C, Bolz HJ, Millan J, Hamel C, Malcolm S, Claustres M, Roux AF (2012) Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for diagnosis and therapy. Hum Mutat 33(1):104\u2013108. https:\/\/doi.org\/10.1002\/humu.21634","journal-title":"Hum Mutat"},{"issue":"10","key":"3_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.89","volume":"5","author":"RW Slijkerman","year":"2016","unstructured":"Slijkerman RW, Vach\u00e9 C, Dona M, Garc\u00eda-Garc\u00eda G, Claustres M, Hetterschijt L, Peters TA, Hartel BP, Pennings RJ, Millan JM, Aller E, Garanto A, Collin RW, Kremer H, Roux AF, Van Wijk E (2016) Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation. Mol Ther Nucleic Acids 5(10):e381. https:\/\/doi.org\/10.1038\/mtna.2016.89","journal-title":"Mol Ther Nucleic Acids"},{"key":"3_CR129","unstructured":"ProQR (2017) ProQR\u2019s drug candidate QRX-411 for usher syndrome receives orphan drug designation from FDA and EMA. https:\/\/www.google.com\/search?q=ProQR%E2%80%99s+drug+candidate+QRX-411+for+usher+syndrome+receives+orphan+drug+designation+from+FDA+and+EMA&rlz=1C1GCEU_enIN1080IN1080&oq=ProQR%E2%80%99s+drug+candidate+QRX-411+for+usher+syndrome+receives+orphan+drug+designation+from+FDA+and+EMA&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRiPAjIHCAIQIRiPAtIBBzMyM2owajSoAgCwAgA&sourceid=chrome&ie=UTF-8. Accessed Oct 24 2024"},{"issue":"10","key":"3_CR130","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/humu.22608","volume":"35","author":"D Baux","year":"2014","unstructured":"Baux D, Blanchet C, Hamel C, Meunier I, Larrieu L, Faug\u00e8re V, Vach\u00e9 C, Castorina P, Puech B, Bonneau D, Malcolm S, Claustres M, Roux AF (2014) Enrichment of LOVD-USHbases with 152 USH2A genotypes defines an extensive mutational spectrum and highlights missense hotspots. Hum Mutat 35(10):1179\u20131186. https:\/\/doi.org\/10.1002\/humu.22608","journal-title":"Hum Mutat"},{"issue":"1","key":"3_CR131","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, Magin TM, Marinkovich MP, Marshall JF, McGrath JA, Mellerio JE, Polson R, Heagerty AH (2020) Epidermolysis bullosa. Nat Rev Dis Primers 6(1):78. https:\/\/doi.org\/10.1038\/s41572-020-0210-0","journal-title":"Nat Rev Dis Primers"},{"key":"3_CR132","doi-asserted-by":"publisher","unstructured":"Zorina A, Zorin V, Isaev A, Kudlay D, Manturova N, Ustugov A, Kopnin P (2024) Current status of biomedical products for gene and cell therapy of recessive dystrophic epidermolysis bullosa. Int J Mol Sci 25(19). https:\/\/doi.org\/10.3390\/ijms251910270","DOI":"10.3390\/ijms251910270"},{"issue":"12","key":"3_CR133","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","volume":"136","author":"S Turczynski","year":"2016","unstructured":"Turczynski S, Titeux M, Tonasso L, D\u00e9cha A, Ishida-Yamamoto A, Hovnanian A (2016) Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model. J Invest Dermatol 136(12):2387\u20132395. https:\/\/doi.org\/10.1016\/j.jid.2016.07.029","journal-title":"J Invest Dermatol"},{"issue":"10","key":"3_CR134","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00403-003-0444-1","volume":"295","author":"T Murata","year":"2004","unstructured":"Murata T, Masunaga T, Ishiko A, Shimizu H, Nishikawa T (2004) Differences in recurrent COL7A1 mutations in dystrophic epidermolysis bullosa: ethnic-specific and worldwide recurrent mutations. Arch Dermatol Res 295(10):442\u2013447. https:\/\/doi.org\/10.1007\/s00403-003-0444-1","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"3_CR135","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1046\/j.1523-1747.2002.19606.x","volume":"119","author":"R Gardella","year":"2002","unstructured":"Gardella R, Castiglia D, Posteraro P, Bernardini S, Zoppi N, Paradisi M, Tadini G, Barlati S, McGrath JA, Zambruno G, Colombi M (2002) Genotype-phenotype correlation in italian patients with dystrophic epidermolysis bullosa. J Invest Dermatol 119(6):1456\u20131462. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.19606.x","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3_CR136","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1365-4362.2000.00975.x","volume":"39","author":"JC Salas-Alanis","year":"2000","unstructured":"Salas-Alanis JC, Amaya-Guerra M, McGrath JA (2000) The molecular basis of dystrophic epidermolysis bullosa in Mexico. Int J Dermatol 39(6):436\u2013442","journal-title":"Int J Dermatol"},{"issue":"5","key":"3_CR137","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1365-2133.2005.06542.x","volume":"152","author":"M Csikos","year":"2005","unstructured":"Csikos M, Szocs HI, Laszik A, Mecklenbeck S, Horvath A, Karpati S, Bruckner-Tuderman L (2005) High frequency of the 425A-->G splice-site mutation and novel mutations of the COL7A1 gene in central Europe: significance for future mutation detection strategies in dystrophic epidermolysis bullosa. Br J Dermatol 152(5):879\u2013886. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06542.x","journal-title":"Br J Dermatol"},{"issue":"6","key":"3_CR138","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1046\/j.1523-1747.1999.00601.x","volume":"112","author":"K Tamai","year":"1999","unstructured":"Tamai K, Murai T, Mayama M, Kon A, Nomura K, Sawamura D, Hanada K, Hashimoto I, Shimizu H, Masunaga T, Nishikawa T, Mitsuhashi Y, Ishida-Yamamoto A, Ikeda S, Ogawa H, McGrath JA, Pulkkinen L, Uitto J (1999) Recurrent COL7A1 mutations in Japanese patients with dystrophic epidermolysis bullosa: positional effects of premature termination codon mutations on clinical severity. Japanese collaborative study group on epidermolysis bullosa. J Invest Dermatol 112(6):991\u2013993. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00601.x","journal-title":"J Invest Dermatol"},{"issue":"1","key":"3_CR139","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2230.1999.00404.x","volume":"24","author":"R Mohammedi","year":"1999","unstructured":"Mohammedi R, Mellerio JE, Ashton GH, Eady RA, McGrath JA (1999) A recurrent COL7A1 mutation, R2814X, in British patients with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol 24(1):37\u201339","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"3_CR140","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1600-0625.2008.00723.x","volume":"17","author":"N Dang","year":"2008","unstructured":"Dang N, Murrell DF (2008) Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 17(7):553\u2013568. https:\/\/doi.org\/10.1111\/j.1600-0625.2008.00723.x","journal-title":"Exp Dermatol"},{"issue":"2","key":"3_CR141","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/1523-1747.ep12319792","volume":"109","author":"JE Mellerio","year":"1997","unstructured":"Mellerio JE, Dunnill MG, Allison W, Ashton GH, Christiano AM, Uitto J, Eady RA, McGrath JA (1997) Recurrent mutations in the type VII collagen gene (COL7A1) in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 109(2):246\u2013249","journal-title":"J Invest Dermatol"},{"issue":"3","key":"3_CR142","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2024.04.073","volume":"91","author":"JY So","year":"2024","unstructured":"So JY, Nazaroff J, Yenamandra VK, Gorell ES, Harris N, Fulchand S, Eid E, Dolorito JA, Marinkovich MP, Tang JY (2024) Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 91(3):448\u2013456. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.073","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"3_CR143","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","volume":"126","author":"M Goto","year":"2006","unstructured":"Goto M, Sawamura D, Nishie W, Sakai K, McMillan JR, Akiyama M, Shimizu H (2006) Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol 126(12):2614\u20132620. https:\/\/doi.org\/10.1038\/sj.jid.5700435","journal-title":"J Invest Dermatol"},{"issue":"35","key":"3_CR144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401781121","volume":"121","author":"N Pironon","year":"2024","unstructured":"Pironon N, Bourrat E, Prost C, Chen M, Woodley DT, Titeux M, Hovnanian A (2024) Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa. Proc Natl Acad Sci USA 121(35):e2401781121. https:\/\/doi.org\/10.1073\/pnas.2401781121","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"3_CR145","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s13555-024-01227-8","volume":"14","author":"S Danescu","year":"2024","unstructured":"Danescu S, Negrutiu M, Has C (2024) Treatment of epidermolysis bullosa and future directions: a review. Dermatol Ther (Heidelb) 14(8):2059\u20132075. https:\/\/doi.org\/10.1007\/s13555-024-01227-8","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3_CR146","doi-asserted-by":"publisher","unstructured":"Hainzl S, Trattner L, Liemberger B, Bischof J, Kocher T, Ablinger M, Nystr\u00f6m A, Obermayer A, Klausegger A, Guttmann-Gruber C, Wally V, Bauer JW, Hofbauer JP, Koller U (2024) Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa. Int J Mol Sci 25(2). https:\/\/doi.org\/10.3390\/ijms25020761","DOI":"10.3390\/ijms25020761"},{"issue":"7203","key":"3_CR147","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature07204","volume":"454","author":"SJ Galli","year":"2008","unstructured":"Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454(7203):445\u2013454. https:\/\/doi.org\/10.1038\/nature07204","journal-title":"Nature"},{"issue":"679","key":"3_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add2563","volume":"15","author":"CA Akdis","year":"2023","unstructured":"Akdis CA, Akdis M, Boyd SD, Sampath V, Galli SJ, Nadeau KC (2023) Allergy: mechanistic insights into new methods of prevention and therapy. Sci Transl Med 15(679):eadd2563. https:\/\/doi.org\/10.1126\/scitranslmed.add2563","journal-title":"Sci Transl Med"},{"key":"3_CR149","doi-asserted-by":"publisher","first-page":"1213320","DOI":"10.3389\/fmed.2023.1213320","volume":"10","author":"KN Dileepan","year":"2023","unstructured":"Dileepan KN, Raveendran VV, Sharma R, Abraham H, Barua R, Singh V, Sharma R, Sharma M (2023) Mast cell-mediated immune regulation in health and disease. Front Med (Lausanne) 10:1213320. https:\/\/doi.org\/10.3389\/fmed.2023.1213320","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3_CR150","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-021-00622-y","volume":"22","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Elieh-Ali-Komi D, Metz M, Siebenhaar F, Maurer M (2022) Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol 22(5):294\u2013308. https:\/\/doi.org\/10.1038\/s41577-021-00622-y","journal-title":"Nat Rev Immunol"},{"key":"3_CR151","doi-asserted-by":"publisher","unstructured":"Arthur GK, Cruse G (2022) Regulation of trafficking and signaling of the high affinity IgE receptor by Fc\u03b5RI\u03b2 and the potential impact of Fc\u03b5RI\u03b2 splicing in allergic inflammation. Int J Mol Sci 23(2). https:\/\/doi.org\/10.3390\/ijms23020788","DOI":"10.3390\/ijms23020788"},{"issue":"1","key":"3_CR152","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0378-1119(00)00598-9","volume":"264","author":"K Ishibashi","year":"2001","unstructured":"Ishibashi K, Suzuki M, Sasaki S, Imai M (2001) Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor. Gene 264(1):87\u201393","journal-title":"Gene"},{"issue":"10","key":"3_CR153","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1096\/fj.10-158378","volume":"24","author":"G Cruse","year":"2010","unstructured":"Cruse G, Kaur D, Leyland M, Bradding P (2010) A novel FcepsilonRIbeta-chain truncation regulates human mast cell proliferation and survival. FASEB J 24(10):4047\u20134057. https:\/\/doi.org\/10.1096\/fj.10-158378","journal-title":"FASEB J"},{"issue":"26","key":"3_CR154","doi-asserted-by":"publisher","first-page":"15323","DOI":"10.1016\/S0021-9258(19)84829-9","volume":"264","author":"C Ra","year":"1989","unstructured":"Ra C, Jouvin MH, Kinet JP (1989) Complete structure of the mouse mast cell receptor for IgE (Fc epsilon RI) and surface expression of chimeric receptors (rat-mouse-human) on transfected cells. J Biol Chem 264(26):15323\u201315327","journal-title":"J Biol Chem"},{"issue":"4","key":"3_CR155","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1074-7613(00)80556-7","volume":"8","author":"D Dombrowicz","year":"1998","unstructured":"Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP (1998) Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 8(4):517\u2013529","journal-title":"Immunity"},{"issue":"5","key":"3_CR156","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.immuni.2013.04.007","volume":"38","author":"G Cruse","year":"2013","unstructured":"Cruse G, Beaven MA, Ashmole I, Bradding P, Gilfillan AM, Metcalfe DD (2013) A truncated splice-variant of the FcepsilonRIbeta receptor subunit is critical for microtubule formation and degranulation in mast cells. Immunity 38(5):906\u2013917. https:\/\/doi.org\/10.1016\/j.immuni.2013.04.007","journal-title":"Immunity"},{"issue":"5","key":"3_CR157","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1074-7613(03)00115-8","volume":"18","author":"E Donnadieu","year":"2003","unstructured":"Donnadieu E, Jouvin MH, Rana S, Moffatt MF, Mockford EH, Cookson WO, Kinet JP (2003) Competing functions encoded in the allergy-associated F(c)epsilonRIbeta gene. Immunity 18(5):665\u2013674","journal-title":"Immunity"},{"issue":"49","key":"3_CR158","doi-asserted-by":"publisher","first-page":"14115","DOI":"10.1073\/pnas.1608520113","volume":"113","author":"G Cruse","year":"2016","unstructured":"Cruse G, Yin Y, Fukuyama T, Desai A, Arthur GK, B\u00e4umer W, Beaven MA, Metcalfe DD (2016) Exon skipping of Fc\u03b5RI\u03b2 eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy. Proc Natl Acad Sci USA 113(49):14115\u201314120. https:\/\/doi.org\/10.1073\/pnas.1608520113","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR159","doi-asserted-by":"publisher","first-page":"1006741","DOI":"10.3389\/fimmu.2023.1006741","volume":"14","author":"BA Hedgespeth","year":"2023","unstructured":"Hedgespeth BA, Snider DB, Bitting KJ, Cruse G (2023) The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis. Front Immunol 14:1006741. https:\/\/doi.org\/10.3389\/fimmu.2023.1006741","journal-title":"Front Immunol"},{"key":"3_CR160","unstructured":"Akesson LS, Savarirayan R (2024) Fibrodysplasia ossificans progressiva. GeneReviews\u00ae[Internet]"},{"key":"3_CR161","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bone.2017.09.014","volume":"109","author":"RJ Pignolo","year":"2017","unstructured":"Pignolo RJ, Kaplan FS (2017) Clinical staging of Fibrodysplasia Ossificans Progressiva (FOP). Bone 109:111. https:\/\/doi.org\/10.1016\/j.bone.2017.09.014","journal-title":"Bone"},{"key":"3_CR162","doi-asserted-by":"publisher","unstructured":"Mejias Rivera L, Shore EM, Mourkioti F (2024) Cellular and molecular mechanisms of heterotopic ossification in Fibrodysplasia Ossificans Progressiva. Biomedicines 12(4). https:\/\/doi.org\/10.3390\/biomedicines12040779","DOI":"10.3390\/biomedicines12040779"},{"key":"3_CR163","doi-asserted-by":"publisher","unstructured":"Kaliya-Perumal AK, Carney TJ, Ingham PW (2020) Fibrodysplasia ossificans progressiva: current concepts from bench to bedside. Dis Model Mech 13(9). https:\/\/doi.org\/10.1242\/dmm.046441","DOI":"10.1242\/dmm.046441"},{"issue":"5","key":"3_CR164","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5):525\u2013527. https:\/\/doi.org\/10.1038\/ng1783","journal-title":"Nat Genet"},{"issue":"6","key":"3_CR165","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1359\/jbmr.091110","volume":"25","author":"M van Dinther","year":"2010","unstructured":"van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25(6):1208\u20131215. https:\/\/doi.org\/10.1359\/jbmr.091110","journal-title":"J Bone Miner Res"},{"issue":"7","key":"3_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069096","volume":"8","author":"S Shi","year":"2013","unstructured":"Shi S, Cai J, de Gorter DJ, Sanchez-Duffhues G, Kemaladewi DU, Hoogaars WM, Aartsma-Rus A et al (2013) Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS One 8(7):e69096. https:\/\/doi.org\/10.1371\/journal.pone.0069096","journal-title":"PLoS One"},{"issue":"1","key":"3_CR167","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yexcr.2014.01.026","volume":"325","author":"M Veltrop","year":"2014","unstructured":"Veltrop M, Aartsma-Rus A (2014) Antisense-mediated exon skipping: taking advantage of a trick from mother nature to treat rare genetic diseases. Exp Cell Res 325(1):50\u201355. https:\/\/doi.org\/10.1016\/j.yexcr.2014.01.026","journal-title":"Exp Cell Res"},{"issue":"3","key":"3_CR168","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/nat.2021.0009","volume":"32","author":"R Maruyama","year":"2022","unstructured":"Maruyama R, Nguyen Q, Roshmi RR, Touznik A, Yokota T (2022) Allele-selective LNA Gapmers for the treatment of Fibrodysplasia Ossificans Progressiva Knock down the pathogenic ACVR1(R206H) transcript and inhibit osteogenic differentiation. Nucleic Acid Ther 32(3):185\u2013193. https:\/\/doi.org\/10.1089\/nat.2021.0009","journal-title":"Nucleic Acid Ther"},{"issue":"13","key":"3_CR169","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"key":"3_CR170","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/hum.2023.026","volume":"34","author":"AM Aartsma-Rus","year":"2023","unstructured":"Aartsma-Rus AM (2023) The future of exon skipping for Duchenne muscular dystrophy. Hum Gene Ther 34:372. https:\/\/doi.org\/10.1089\/hum.2023.026","journal-title":"Hum Gene Ther"},{"issue":"1","key":"3_CR171","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.chembiol.2023.09.005","volume":"31","author":"CR Hofman","year":"2024","unstructured":"Hofman CR, Corey DR (2024) Targeting RNA with synthetic oligonucleotides: clinical success invites new challenges. Cell Chem Biol 31(1):125\u2013138. https:\/\/doi.org\/10.1016\/j.chembiol.2023.09.005","journal-title":"Cell Chem Biol"},{"key":"3_CR172","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/nat.2024.0031","volume":"34","author":"D O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly D, van Roon-Mom W, Aartsma-Rus A (2024) A guide to chemical considerations for the pre-clinical development of oligonucleotides. Nucleic Acid Ther 34:295. https:\/\/doi.org\/10.1089\/nat.2024.0031","journal-title":"Nucleic Acid Ther"},{"issue":"9","key":"3_CR173","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1039\/d4md00394b","volume":"15","author":"M Blitek","year":"2024","unstructured":"Blitek M, Phongsavanh X, Goyenvalle A (2024) The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy. RSC Med Chem 15(9):3017\u20133025. https:\/\/doi.org\/10.1039\/d4md00394b","journal-title":"RSC Med Chem"},{"issue":"2","key":"3_CR174","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/jnd-160146","volume":"3","author":"A Goyenvalle","year":"2016","unstructured":"Goyenvalle A, Leumann C, Garcia L (2016) Therapeutic potential of Tricyclo-DNA antisense oligonucleotides. J Neuromuscul Dis 3(2):157\u2013167. https:\/\/doi.org\/10.3233\/jnd-160146","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"3_CR175","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle A, Griffith G, Babbs A, El Andaloussi S, Ezzat K, Avril A, Dugovic B, Chaussenot R, Ferry A, Voit T, Amthor H, Buhr C, Schurch S, Wood MJ, Davies KE, Vaillend C, Leumann C, Garcia L (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 21(3):270\u2013275. https:\/\/doi.org\/10.1038\/nm.3765","journal-title":"Nat Med"},{"key":"3_CR176","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","volume":"8","author":"K Relizani","year":"2017","unstructured":"Relizani K, Griffith G, Echevarr\u00eda L, Zarrouki F, Facchinetti P, Vaillend C, Leumann C, Garcia L, Goyenvalle A (2017) Efficacy and safety profile of Tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model. Mol Ther Nucleic Acids 8:144\u2013157. https:\/\/doi.org\/10.1016\/j.omtn.2017.06.013","journal-title":"Mol Ther Nucleic Acids"},{"key":"3_CR177","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.omtn.2023.03.009","volume":"32","author":"A Saoudi","year":"2023","unstructured":"Saoudi A, Barberat S, le Coz O, Vacca O, Doisy Caquant M, Tensorer T, Sliwinski E, Garcia L, Muntoni F, Vaillend C, Goyenvalle A (2023) Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice. Mol Ther Nucleic Acids 32:173\u2013188. https:\/\/doi.org\/10.1016\/j.omtn.2023.03.009","journal-title":"Mol Ther Nucleic Acids"},{"issue":"13","key":"3_CR178","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/nar\/gkf412","volume":"30","author":"D Renneberg","year":"2002","unstructured":"Renneberg D, Bouliong E, Reber U, Sch\u00fcmperli D, Leumann CJ (2002) Antisense properties of tricyclo-DNA. Nucleic Acids Res 30(13):2751\u20132757. https:\/\/doi.org\/10.1093\/nar\/gkf412","journal-title":"Nucleic Acids Res"},{"key":"3_CR179","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.omtn.2017.02.009","volume":"7","author":"V Robin","year":"2017","unstructured":"Robin V, Griffith G, Carter JL, Leumann CJ, Garcia L, Goyenvalle A (2017) Efficient SMN rescue following subcutaneous Tricyclo-DNA antisense oligonucleotide treatment. Mol Ther Nucleic Acids 7:81\u201389. https:\/\/doi.org\/10.1016\/j.omtn.2017.02.009","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"3_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.46","volume":"5","author":"L Cao","year":"2016","unstructured":"Cao L, Han G, Lin C, Gu B, Gao X, Moulton HM, Seow Y, Yin H (2016) Fructose promotes uptake and activity of oligonucleotides with different chemistries in a context-dependent manner in mdx mice. Mol Ther Nucleic Acids 5(6):e329. https:\/\/doi.org\/10.1038\/mtna.2016.46","journal-title":"Mol Ther Nucleic Acids"},{"key":"3_CR181","doi-asserted-by":"publisher","first-page":"10981","DOI":"10.1038\/ncomms10981","volume":"7","author":"G Han","year":"2016","unstructured":"Han G, Gu B, Cao L, Gao X, Wang Q, Seow Y, Zhang N, Wood MJ, Yin H (2016) Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. Nat Commun 7:10981. https:\/\/doi.org\/10.1038\/ncomms10981","journal-title":"Nat Commun"},{"key":"3_CR182","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.omtn.2019.09.012","volume":"18","author":"G Han","year":"2019","unstructured":"Han G, Gu B, Lin C, Ning H, Song J, Gao X, Moulton HM, Yin H (2019) Hexose potentiates peptide-conjugated Morpholino oligomer efficacy in cardiac muscles of dystrophic mice in an age-dependent manner. Mol Ther Nucleic Acids 18:341\u2013350. https:\/\/doi.org\/10.1016\/j.omtn.2019.09.012","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"3_CR183","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddv460","volume":"25","author":"WD Coley","year":"2016","unstructured":"Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen JH, Rayavarapu S, Novak JS, Nearing M, Quinn JL, Saunders A, Dolan C, Andrews W, Lammert C, Austin A, Partridge TA, Cox GA, Lutz C, Nagaraju K (2016) Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet 25(1):130\u2013145. https:\/\/doi.org\/10.1093\/hmg\/ddv460","journal-title":"Hum Mol Genet"},{"issue":"2","key":"3_CR184","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","volume":"17","author":"EH Niks","year":"2017","unstructured":"Niks EH, Aartsma-Rus A (2017) Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 17(2):225\u2013236. https:\/\/doi.org\/10.1080\/14712598.2017.1271872","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"3_CR185","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.2353\/ajpath.2010.090887","volume":"176","author":"S Fukada","year":"2010","unstructured":"Fukada S, Morikawa D, Yamamoto Y, Yoshida T, Sumie N, Yamaguchi M, Ito T, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Yamamoto H (2010) Genetic background affects properties of satellite cells and mdx phenotypes. Am J Pathol 176(5):2414\u20132424. https:\/\/doi.org\/10.2353\/ajpath.2010.090887","journal-title":"Am J Pathol"},{"issue":"1","key":"3_CR186","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada S, Yokota T (2016) Current translational research and murine models for Duchenne muscular dystrophy. J Neuromuscul Dis 3(1):29\u201348","journal-title":"J Neuromuscul Dis"},{"key":"3_CR187","doi-asserted-by":"publisher","first-page":"38371","DOI":"10.1038\/srep38371","volume":"6","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Maruyama R, Lim KR, Fukada SI, Yokota T (2016) Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA\/2 background. Sci Rep 6:38371. https:\/\/doi.org\/10.1038\/srep38371","journal-title":"Sci Rep"},{"issue":"1","key":"3_CR188","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s42003-024-06222-5","volume":"7","author":"M Otake","year":"2024","unstructured":"Otake M, Imamura M, Enya S, Kangawa A, Shibata M, Ozaki K, Kimura K, Ono E, Aoki Y (2024) Severe cardiac and skeletal manifestations in DMD-edited microminipigs: an advanced surrogate for Duchenne muscular dystrophy. Commun Biol 7(1):523. https:\/\/doi.org\/10.1038\/s42003-024-06222-5","journal-title":"Commun Biol"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:06:34Z","timestamp":1780747594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":188,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_3","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}